Viewing StudyNCT06022757

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-06 @ 7:29 PM
Last Modification Date: 2024-10-26 @ 3:07 PM
Study NCT ID: NCT06022757
Status: RECRUITING
Last Update Posted: 2024-02-23
First Post: 2023-08-17
Brief Title: Study of XNW5004 Tablet in Combination With KEYTRUDA Pembrolizumab in Subjects With Advanced Solid Tumors Who Failed Standard Treatments KEYNOTE F19
Sponsor: Evopoint Biosciences Inc
Organization: Evopoint Biosciences Inc
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Urothelial Carcinoma
Prostate Cancer
Small-cell Lung Cancer
Non-small Cell Lung Cancer
Cervical Cancer
Other Solid Tumors
Keywords:
Name View
XNW5004 View
EZH2 inhibitor View
KEYTRUDA pembrolizumab View
immune checkpoint inhibitors View